A Phase I/II Study of Azacitidine, Docetaxel, and Prednisone for Metastatic Prostate Cancer Patients
Status:
Terminated
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
Azacitidine can reverse clinical resistance to docetaxel through upregulation of Growth
Arrest and DNA Damage inducible alpha (GADD45α) and other epigenetically regulated genes.